Phage therapy - the therapeutic use of bacteriophages (phages) to treat bacterial infections - is gaining rapid interest within the CF community. This approach offers several advantages over traditional antibacterial therapy (antibiotics), including specificity to pathogenic bacteria, activity against biofilm-forming microorganisms, and efficacy irrespective of multidrug resistance. Given the incidence of difficult-to-treat infections in people with CF (pwCF), and the limitations of current antimicrobial options, there is a pressing need to explore how to integrate phage therapy more systematically within CF care. To address this need, a dedicated body under the ECFS is coordinating, facilitating, and advocating for responsible use of phage therapy in pwCF, particularly in life-threatening or otherwise intractable infections, by fostering international collaboration, knowledge exchange, and the development of practical frameworks.